Company Overview and News

0
Axis Reit: Property sector moving forward on positive note in 2h18

2018-07-14 malaymail
KUALA LUMPUR, July 14 — The property sector is expected to do better in the second half of 2018 (2H18), opposing the general perception of the bearish property sector, as the knee-jerk reaction due to 14th General Election subsided, Axis Real Estate Investment Trust (Reit) Head of Investments Siva Shanker said.
5106

1
Proposed Johor acquisitions expected to be yield-accretive for Axis REIT

2018-06-11 theedgemarkets
Axis Real Estate Investment Trust (June 8, RM1.54) Maintain hold with an unchanged target price (TP) of RM1.44: Axis Real Estate Investment Trust (REIT) has proposed to acquire two industrial properties with a combined area of approximately 251,000 sq ft, situated within Kawasan Perindustrian i-Park, Bandar Indahpura, Kulai, Johor.
5106

1
Trading ideas: Straits Inter Logistics, Axis Reit, PUC

2018-06-08 thestar.com.my
KUALA LUMPUR: Straits Inter Logistics Bhd , Axis Real Estate Investment Trust and PUC Bhd are among the stocks to watch on Friday, according to JF Apex Research.
5106

1
Axis REIT plans to buy Johor industrial land

2018-06-08 thestar.com.my
Axis REIT said the proposed acquisition would help the company achieve growth in its net asset value per unit by acquiring high-quality, earnings-accretive property with a strong recurring rental income
5106

1
Analyst Reports

2018-06-05 thestar.com.my
Gamuda’s remaining order book of RM13.5bil, which includes RM6.6bil for a project delivery partner contract, will sustain construction activities over the next three years.
5106

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...